Edition:
United States

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

68.95EUR
11:35am EDT
Change (% chg)

€0.25 (+0.36%)
Prev Close
€68.70
Open
€69.45
Day's High
€69.45
Day's Low
€68.05
Volume
49,923
Avg. Vol
91,788
52-wk High
€71.00
52-wk Low
€49.85

Latest Key Developments (Source: Significant Developments)

DiaSorin launches Liaison androstenedione test
Tuesday, 16 May 2017 04:52am EDT 

May 16 (Reuters) - DIASORIN SPA ::LAUNCHES NEW LIAISON ANDROSTENEDIONE TEST FOR EVALUATION OF ADRENAL AND GONADAL FUNCTIONALITY.LIAISON ANDROSTENEDIONE TEST AVAILABLE WORLDWIDE WITH EXCEPTION OF U.S..ELEVATED ANDROSTENEDIONE LEVELS IN BLOOD ARE ASSOCIATED WITH HORMONE-RELATED DISEASES SUCH AS POLYCYSTIC OVARIAN SYNDROME (PCOS), CONGENITAL ADRENAL HYPERPLASIA (CAH) AND ADRENAL GLAND TUMORS.  Full Article

Diasorin Q1 net profit rises to EUR 32.0 million
Monday, 8 May 2017 11:28am EDT 

May 8 (Reuters) - DIASORIN SPA :Q1 REVENUE EUR 157.5 MILLION VERSUS EUR 124.5 MILLION YEAR AGO.Q1 NET PROFIT EUR 32.9 MILLION VERSUS EUR 24.7 MILLION YEAR AGO.SEES FY 2017 REVENUES GROWTH EQUAL TO +11% AT CER COMPARED WITH 2016.SEES FY 2017 EBITDA GROWTH EQUAL TO +11% AT CER COMPARED WITH 2016.  Full Article

Diasorin receives authorization for distribution of Zika IgM test in Europe
Friday, 21 Apr 2017 10:33am EDT 

April 21 (Reuters) - Diasorin SpA ::Receives authorization for distribution of Zika IgM test in Europe.  Full Article

DiaSorin FY net profit up 12 pct at EUR 112.6 mln, proposes dividend of EUR 0.80/shr
Wednesday, 8 Mar 2017 08:40am EST 

DiaSorin SpA : Proposes cash dividend of 0.80 euro per share, up 23.1 pct versus 2015 . FY net profit 112.6 million euros ($118.70 million) versus 100.5 million euros a year ago . FY revenue 569.3 million euros versus 499.2 million euros a year ago . 2017 guidance, including unit Focus: revenues up around 11 pct at constant exchange rates (CER), compared with 2016 .2017 guidance, including unit Focus: EBITDA up around 11 pct at CER, compared with 2016.  Full Article

DiaSorin launches test Simplexa C. Difficile Direct in the U.S.
Tuesday, 21 Feb 2017 04:31am EST 

DiaSorin SpA : Launches molecular test Simplexa C. Difficile Direct in the United States .Clostridium difficile Infection (CDI) is a cause of antibiotic-associated diarrhea and colitis.  Full Article

DiaSorin launches test Liaison FGF 23 for chronic kidney disease
Thursday, 26 Jan 2017 05:30am EST 

DiaSorin SpA : Launches test Liaison FGF 23, an automated marker for chronic kidney disease .Liaison FGF 23 to be available worldwide with the exception of the U.S..  Full Article

Diasorin Q3 net profit rises to EUR 28.7 mln
Thursday, 10 Nov 2016 07:15am EST 

Diasorin SpA : Reports Q3 net profit 28.7 million euros ($31.21 million)versus 23.2 million euros a year ago . Q3 revenue 147.0 million euros versus 123.2 million euros a year ago .Confirms previous guidance on revenues and EBITDA for 2016.  Full Article

DiaSorin and Beckman Coulter form partnership to bring hepatitis and HIV tests to U.S.
Tuesday, 30 Aug 2016 04:03am EDT 

DiaSorin SpA : DiaSorin and Beckman Coulter Diagnostics (Beckman Coulter) form strategic partnership to bring Liaison XL hepatitis and HIV products to the United States market . Will work together with Beckman Coulter to submit the products to food and drug administration (FDA) for approval and commercialization in the United States . To offer customers in the United States access to the line of hepatitis and HIV products that can be run on Liaison XL LAS connected to Beckman Coulter's automation solutions . DiaSorin will retain right to commercialize products on Liaison XL stand-alone systems in hospital labs where total laboratory automation (TLA) is not required .Estimates that total available market in the United States for these products, excluding blood bank testing, exceeds $500 million.  Full Article

U.S. HHS awards $2.6 mln to Diasorin group to develop Zika test
Monday, 22 Aug 2016 10:44am EDT 

U.S. Department of Health and Human Services : U.S. HHS Awards $2.6 Million To Diasorin Group To Develop Rapid, High Capacity Zika diagnostic laboratory test . Contract supports development of diagnostic test, manufacturing preparations,clinical trials that could support application for FDA clearance Further company coverage: [DIAS.MI] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

DiaSorin Q2 net profit up 12.0 pct to EUR 29.4 mln
Thursday, 4 Aug 2016 07:57am EDT 

DiaSorin SpA : Q2 net profit 29.4 million euros ($32.73 million), up 12.0 percent year on year . Q2 revenue 141.7 million euros versus 127.5 million euros a year ago . Revises upwards the previous guidance on revenues and EBITDA for 2016, excluding the additional contribution resulting from the recent acquisition of the Focus Diagnostics' business . FY 2016 revenues: sees growth between 6 percent and 7 percent at CER (Constant Exchange Rate) compared with 2015 (previous guidance: growth between 5 percent and 6 percent at CER) .FY 2016 EBITDA: sees growth equal to around 9 percent at CER compared with 2015 (previous guidance: growth equal to around 8 percent at CER).  Full Article

More From Around the Web

BRIEF-DiaSorin launches test Liaison SHBG to diagnose androgen-related disorders

* LAUNCHES TEST LIAISON SHBG FOR DIAGNOSIS OF DISORDERS RELATED TO THE ANDROGEN HORMONES